Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
about
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryFirst-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertensionBeta-blockers for hypertensionBeta-blockers for hypertensionAngiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney diseaseFirst-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertensionStandards of medical care in diabetes--2012Neurohumoral stimulation in type-2-diabetes as an emerging disease conceptDeterminants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey.Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trialsCardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-AnalysesCarotid artery intima-media thickness and the renin-angiotensin systemGram negative wound infection in hospitalised adult burn patients--systematic review and metanalysis-Fetal stress and programming of hypoxic/ischemic-sensitive phenotype in the neonatal brain: mechanisms and possible interventionsObesity and kidney protectionManaging hypertension in the elderly: a common chronic disease with increasing ageUpdate on RAAS Modulation for the Treatment of Diabetic Cardiovascular DiseaseUS Hypertension Management Guidelines: A Review of the Recent Past and Recommendations for the FutureTreatment of metabolic syndromeChronobiologically explored effects of TelmisartanUnder-prescribing of cardiovascular therapies for diabetes in primary careCardioprotective medication use in hemodialysis patientsThe 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapyRole of angiotensin II in cardiovascular disease therapeutic implications of more than a century of researchDiscovery of novel GPVI receptor antagonists by structure-based repurposingLosartan improves aortic endothelium-dependent relaxation via proline-rich tyrosine kinase 2/Src/Akt pathway in type 2 diabetic Goto-Kakizaki rats.Hypertension-Related Morbidity and Mortality in African Americans?Why We Need to Do BetterStandards of medical care in diabetes--2013Beta-blockers for hypertension.Why not prescribe the best drugs for hypertension now?Diabetic cardiovascular disease: getting to the heart of the matter.Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis.Quantification of cardiomyocyte hypertrophy by cardiac magnetic resonance: implications for early cardiac remodeling.Frequency of cardiovascular events in patients treated with anti hypertensive agents: A cohort study based on claims data generated by primary care practice.Morbidity and mortality of orthostatic hypotension: implications for management of cardiovascular disease.Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review.Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study.Standards of medical care in diabetes--2010.What can we learn from the recent blood glucose lowering megatrials?Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects.
P2860
Q22241786-A760C08D-8C2D-4840-883E-9C08539EDCE0Q24186647-83C2C10B-40A1-4F95-83C3-8387FC33C4FDQ24201511-4B7445DD-9898-4C81-8C52-D4847C229854Q24202812-EF67F972-F6EA-42FC-9D53-8B401B55B5C2Q24235834-CD7270CB-28B1-4EB2-BE38-A1CB381D49F7Q24240851-FE467230-7BD1-4678-97A8-FA5BD4CED8F9Q24632533-D74C8549-28BE-4FB0-A096-43A885BB6A5CQ24798310-40EE2B6D-3AE1-4232-BFCE-ECFE37B43311Q24814563-E93AB021-9CA2-4877-9A60-8A934C9C1888Q26766599-6679948F-4FCC-4B8B-A0F6-59D1A202002EQ26767278-22699556-CB79-48C4-9BF2-9E199D44BB75Q26851516-D3B60E98-F906-4629-AD05-44957343C479Q26864465-A366AFD4-37F2-44CB-8914-5480A1BA7A81Q26996467-AA2E98D5-25DA-4B52-894F-01DE76840CBBQ27005818-CC1ED1F7-90C6-43DB-9B16-3526933DD0B1Q27011805-8701E793-D20A-47A9-85C5-0238E9B5E8A5Q28077454-A7FC2D7B-0F5D-4161-9715-C0C578EF8289Q28081091-1458115A-18D2-4333-8FF7-77BB60080DF9Q28168652-922B5AD1-70B9-4BD3-9550-C041C71DFF9BQ28174117-021B032D-0F98-45AB-8D78-569E1EE40A19Q28195680-B9CA16D2-12CE-4164-B2AE-27F6E4E6EE61Q28199374-995D738E-7502-4B73-A5B6-E927DD5793C5Q28211654-AA396150-4821-4BC2-9D78-336659764F3BQ28272171-819F80D7-3DDF-434B-956F-F01AC5971E60Q28540147-6A021915-566D-4B6C-89A3-870EEF26925CQ29347083-D60E2133-7903-4B92-BD5B-256B984D9174Q29399489-FE42B941-C9C0-4B4F-8DCE-7CA5DF7D22CDQ29620309-93407729-F845-4AED-B502-BA8CF9C0AD6CQ30238911-7E7E67BE-0204-4BD4-AD1F-108FD572D751Q30333019-6BEDA371-8F2E-4746-8A4B-E10EBFC85CFEQ30451529-8A240BB4-1612-44D8-90F2-5AC263170F66Q30514101-39E20DD0-26A2-4A81-8967-DBCF2CE68FF1Q30659130-16C72E45-AF51-4545-A6B3-F41838FF3692Q30808567-165A9684-C8B3-45AC-B1D8-A6C212B736F8Q33159154-53963CEF-2733-4D52-A0DC-B648BD9A605AQ33300205-0AF80CD3-D47E-438E-BAC6-C9A45CF1E549Q33490033-485662DF-858E-464D-8696-8B6E57611A3AQ33554238-3C5984E2-B446-43C7-9C8C-17882F05F46CQ33558383-F6E6940A-39CA-481D-969D-9DDA4B319132Q33561456-81A74B11-5BB0-483E-A4AC-055C0D29387A
P2860
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Cardiovascular morbidity and m ...... omised trial against atenolol.
@en
Cardiovascular morbidity and m ...... eduction in hypertension study
@nl
type
label
Cardiovascular morbidity and m ...... omised trial against atenolol.
@en
Cardiovascular morbidity and m ...... eduction in hypertension study
@nl
prefLabel
Cardiovascular morbidity and m ...... omised trial against atenolol.
@en
Cardiovascular morbidity and m ...... eduction in hypertension study
@nl
P2093
P50
P1433
P1476
Cardiovascular morbidity and m ...... omised trial against atenolol.
@en
P2093
Frej Fyhrquist
Gareth Beevers
Hans Ibsen
Hans Wedel
Jonathan Edelman
Krister Kristiansson
LIFE Study Group
Lars H Lindholm
Markku S Nieminen
Ole Lederballe-Pedersen
P304
P356
10.1016/S0140-6736(02)08090-X
P407
P577
2002-03-01T00:00:00Z